ERT Cardiac Safety

Cardiac safety concerns are among the leading reasons that promising drugs are halted in development and not brought to market.  At ERT, we’ve overseen 445 cardiac safety drug approvals, completed 6700+ cardiac safety trials and 220+ TQT trials, managed 200K+ sites with 70K+ active sites, and enrolled 2M+ cardiac safety patients. Put our expertise in ECG, Holter and blood pressure data collection & analysis to work for you.

Articles

• Are You Prepared to Replace the Thorough QT Study?

eBook

• Five Reasons to Rethink Paper ECGs

For more information, go to ert.com or email sales@ert.com